Pancreatic Cancer Research

Clinical trialNo phase (not a drug trial)Recruiting

Interaction Between Host, Microenvironment and Immunity on Gastrointestinal Neoplasms

Interaction Between Host, Microenvironment and Immunity on Gastrointestinal Neoplasms: A Retro-prospective Cohort Study

Outcome
Ongoing
Phase
No phase (not a drug trial)
Status
Recruiting
Study type
Interventional
Start
13 January 2021
Expected end
January 2031
Enrollment
6,300 participants
Sites
1
Primary outcomes
Overall survival (OS); Overall survival (OS)
Sponsor type
Academic / other
Results posted
No
Last update
23 February 2022

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The primary objective: association study of characteristics of tumoral microenvironment and immunity of digestive cancers with patients' overall survival (OS).

Detailed description public domain (ClinicalTrials.gov)

The study aims to explore relationship between the molecular subgroups (DNA and RNA analysis), tumor microenvironment, host (immunity system, premetastatic niche, microbiota, metabolism) and survival (prognostic value), response (predictive value) and tolerance (toxicities) to conventional treatments or immunotherapies in digestive cancers, in particular, in colorectal cancer and pancreaticobiliary cancer. This is a prognostic monocentric study which includes 2 parts: * one retrospective observational cohort for which 150 eligible patients (who have being diagnosed between 1998 to 2020) will be entered in the cohort per year during 22 years targeting 3300 patients and * one prospective interventional cohort in which 3000 patients (diagnosis will be done between 2020-2030) will be enrolled during 10 years. 10 years of follow-up for all patients. This cohort is non comparative, non randomized, non control. The enrollment will last 10 years in Digestive Surgery Department, Ambroise Paré Hospital, APHP. There is any change in management of patients' care who will participate to the study, all of the treatment modalities (i.e. surgery, chemotherapy, radiotherapy, immunotherapy, intra-arterial treatments and supportive care) are possible and choice of treatment will be made by investigator physician, after multidisciplinary meeting validation, and according to referential and recommendations of practice in department. Statistic analysis The statistic analysis will be performed and reported according to the international guidelines STROBE for the observational studies.